Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped The study terminated due to low enrollment.

Conditions

Transfusion-dependent β-thalassemia Patients
Cardiac Iron Overload

Interventions

DRUG: Deferasirox
DRUG: Deferoxamine (DFO)

Sponsor

Novartis Pharmaceuticals